Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Companies Involved in Therapeutics Development | 20 | 5 |
| Celgene Corporation | 20 | 1 |
| Eli Lilly and Company | 21 | 1 |
| Merck KGaA | 22 | 1 |
| Onxeo SA | 23 | 1 |
| Vertex Pharmaceuticals Incorporated | 24 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Drug Profiles | 25 | 8 |
| AsiDNA Drug Profile | 25 | 3 |
| CC-115 Drug Profile | 28 | 1 |
| LY-3023414 Drug Profile | 29 | 2 |
| M-3814 Drug Profile | 31 | 1 |
| VX-984 Drug Profile | 32 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Dormant Projects | 33 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Discontinued Products | 34 | 1 |
| DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Featured News &Press Releases | 35 | 10 |
| Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNA patent, extending IP protection in the U.S. until 2031 | 35 | 1 |
| Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNATM patent, extending IP protection in the U.S. until 2031 | 36 | 1 |
| Jun 27, 2016: Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA | 37 | 1 |
| Jun 17, 2015: Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy | 38 | 1 |
| May 30, 2015: DNA Therapeutics presents encouraging results for first-in-class pan DNA repair inhibitor | 38 | 1 |
| Mar 05, 2014: Curie-Cancer and DNA Therapeutics partner in the fight against cancers that resist conventional therapies | 39 | 2 |
| Mar 26, 2012: DNA Therapeutics Announces Completion Of Two First Dose Escalations In DRIIM Trial | 41 | 1 |
| Jan 10, 2012: DNA Therapeutics Announces USPTO's Decision To Grant Third Dbait Patent | 42 | 1 |
| Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Patients In First Cohort Of DRIIM Trial | 42 | 1 |
| Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Treatment Of Patients In First Dose Cohort Of DRIIM Trial | 43 | 1 |
| Nov 25, 2011: DNA Therapeutics's Dbait Receives Chinese Patent Allowance For Treatment Of Metastatic Melanoma | 43 | 1 |
| Aug 22, 2011: DNA Therapeutics Receives Clinical Trial Authorization From French Competent Authority For DNA Therapeutics' First-In-Human Trial | 44 | 1 |
| Mar 31, 2011: DNA Therapeutics Completes Regulatory Toxicology Studies Of DT01 In Rat And Monkey | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |
